Frozen or Powdered MSC Secretome for Growth Factor Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cellular mesenchymal stem cell (MSC) therapies for treating wounds, inflammatory conditions, and autoimmune diseases suffer from therapeutic loss and require tissue matching, necessitating the development of acellular MSC-derived products that provide similar benefits without these drawbacks.
Innovation Solution
Development of MSC secretome compositions, including growth factors, exosomes, and extracellular vesicles, which can be frozen or powdered, and are incorporated into various medical devices for localized treatment of wounds, orthopedic, and spinal disorders, using standard or artificial wound healing conditions to enhance production and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cellular MSC therapies are used to treat wounds and inflammatory conditions, then therapeutic benefits are provided, but therapeutic loss occurs and tissue matching is required
Solution Approach 1:
The patent extracts the therapeutic components (growth factors, extracellular vesicles, secretome) from the cellular MSC structure, creating an acellular preparation that retains therapeutic benefits while eliminating cell attrition and tissue matching requirements. This is achieved through isolation and concentration of MSC-derived bioactive molecules and vesicles.
Solution Approach 2:
The patent creates a copy of the therapeutic function by using acellular MSC-derived preparations that replicate the immunomodulatory and regenerative effects of living MSCs without requiring viable cells. The growth factors and extracellular vesicles serve as functional copies of cellular therapy.
2Reliability
If cellular MSC therapies are used, then therapeutic benefits are provided, but tissue matching between donor and recipient is necessary
Solution Approach 1:
The patent removes the cellular component that necessitates tissue matching, extracting only the secreted therapeutic molecules and extracellular vesicles. This acellular approach eliminates immunological compatibility concerns while preserving therapeutic efficacy.
3Stability of the object's composition
If MSC secretome compositions are frozen or powdered for storage, then stability and ease of storage are improved, but degradation of growth factors and extracellular vesicles may occur
Solution Approach 1:
The patent applies protective coatings and stabilizing formulations to the MSC secretome compositions before freezing or powdering. This preliminary protection prevents degradation during storage and ensures growth factor integrity when the product is later reconstituted and used.
4Quantity of substance
If MSC preparations are cultured under artificial wound healing conditions, then production of growth factors and extracellular vesicles is enhanced, but culturing complexity increases
Solution Approach 1:
The patent modifies culturing parameters (such as oxygen tension, nutrient composition, and growth factors in the medium) to create artificial wound healing conditions that stimulate enhanced production of growth factors and extracellular vesicles by MSCs, optimizing the secretome composition for therapeutic use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MSC secretome compositions effectively treat wounds and orthopedic/spinal disorders with reduced degradation and improved penetration, providing therapeutic benefits without the limitations of cellular therapies.
Implementation Method 1
the MSC secretome compositions (including, but not limited to MSC growth factor and extracellular vesicle compositions and including frozen and/or lyophilized powdered compositions) can be frozen or powdered via lyophilization
Implementation Method 2
the MSC secretome compositions (including, but not limited to MSC growth factor and extracellular vesicle compositions and including frozen and/or lyophilized powdered compositions) can be frozen or powdered via lyophilization
Implementation Method 3
the MSC secretome compositions (including, but not limited to MSC growth factor and extracellular vesicle compositions and including frozen and/or lyophilized powdered compositions) can further comprise a protective coating (such as, for example, a cryoprotectant oligosaccharide and a protein solution) to reduce degradation of the growth factors and extracellular vesicles
Data Source
AI summary
Disclosed are mesenchymal stem cell growth factor compositions and methods of their use to treat skin disorder, alleviate the effects of aging, treat wounds, orthopedic disorders, sexual dysfunction and/or reduce inflammation.